| Year |
Citation |
Score |
| 2020 |
Moas V, Eskridge S, Clouser M, Kurapaty S, Dyke C, Souza J. Incisional Hernia Incidence following Laparotomy for Combat Trauma: Investigating Fifteen Years of US War Surgery. Journal of Trauma-Injury Infection and Critical Care. 89. PMID 32345894 DOI: 10.1097/Ta.0000000000002769 |
0.331 |
|
| 2018 |
Joseph AR, Shaw JL, Clouser MC, MacGregor AJ, Galarneau MR. Impact of Blast Injury on Hearing in a Screened Male Military Population. American Journal of Epidemiology. 187: 7-15. PMID 29309519 DOI: 10.1093/Aje/Kwx199 |
0.343 |
|
| 2016 |
Joseph AR, Horton JL, Clouser MC, MacGregor AJ, Louie M, Galarneau MR. Development of a comprehensive Blast-Related Auditory Injury Database (BRAID). Journal of Rehabilitation Research and Development. 53: 295-306. PMID 27273241 DOI: 10.1682/Jrrd.2015.02.0031 |
0.312 |
|
| 2016 |
Dye JL, Eskridge SL, Tepe V, Clouser MC, Galarneau M. Characterization and Comparison of Combat-Related Injuries in Women During OIF and OEF. Military Medicine. 181: 92-8. PMID 26741907 DOI: 10.7205/Milmed-D-15-00237 |
0.3 |
|
| 2015 |
Oh JS, Do NV, Clouser M, Galarneau M, Philips J, Katschke A, Clasper J, Kuncir EJ. Effectiveness of the combat pelvic protection system in the prevention of genital and urinary tract injuries: An observational study. The Journal of Trauma and Acute Care Surgery. 79: S193-6. PMID 26406430 DOI: 10.1097/Ta.0000000000000735 |
0.335 |
|
| 2013 |
Baker AF, Roe DJ, Laughren C, Cohen JL, Wright HM, Clouser MC, Cui H, Alberts DS, Chambers SK. Investigation of bendamustine HCL in a phase 2 study in women with resistant ovarian cancer. Investigational New Drugs. 31: 160-6. PMID 22580577 DOI: 10.1007/S10637-012-9827-5 |
0.515 |
|
| 2012 |
Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2668-78. PMID 22421191 DOI: 10.1158/1078-0432.Ccr-12-0261 |
0.311 |
|
| 2010 |
Clouser MC, Roe DJ, Foote JA, Harris RB, Alberts DS. Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutrition and Cancer. 62: 1058-66. PMID 21058193 DOI: 10.1080/01635581.2010.492089 |
0.511 |
|
| 2010 |
Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5320-8. PMID 21041183 DOI: 10.1158/1078-0432.Ccr-10-0974 |
0.514 |
|
| 2009 |
Clouser M, Hess LM, Chambers SK. Biomarker targets and novel therapeutics. Cancer Treatment and Research. 149: 85-105. PMID 19763432 DOI: 10.1007/978-0-387-98094-2_4 |
0.348 |
|
| 2009 |
Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiology and Drug Safety. 18: 276-83. PMID 19226541 DOI: 10.1002/Pds.1718 |
0.503 |
|
| 2008 |
Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology. 109: 174-81. PMID 18314182 DOI: 10.1016/J.Ygyno.2008.01.005 |
0.303 |
|
| 2008 |
Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecologic Oncology. 108: 90-4. PMID 17949799 DOI: 10.1200/Jco.2007.25.18_Suppl.5551 |
0.326 |
|
| 2007 |
Alberts DS, Liu PY, Wilczynski SP, Jang A, Moon J, Ward JH, Beck JT, Clouser M, Markman M. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) International Journal of Gynecological Cancer. 17: 784-788. PMID 17343607 DOI: 10.1111/J.1525-1438.2007.00882.X |
0.375 |
|
| 2006 |
Clouser MC, Harris RB, Roe DJ, Saboda K, Ranger-Moore J, Duckett L, Alberts DS. Risk group, skin lesion history, and sun sensitivity reliability in squamous cell skin cancer progression. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 2292-7. PMID 17119060 DOI: 10.1158/1055-9965.Epi-06-0405 |
0.516 |
|
| 2006 |
Clouser MC, Harris RB, Roe DJ. Reliability of Self Reported Sun Exposure Factors American Journal of Epidemiology. 163. DOI: 10.1093/Aje/163.Suppl_11.S91-B |
0.45 |
|
| 2005 |
Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. Journal of the National Cancer Institute. 97: 846-53. PMID 15928305 DOI: 10.1093/Jnci/Dji144 |
0.502 |
|
| Show low-probability matches. |